4//SEC Filing
Dylan-Hyde Tyler 4
Accession 0000899243-18-001348
CIK 0001674416other
Filed
Jan 17, 7:00 PM ET
Accepted
Jan 18, 5:38 PM ET
Size
16.8 KB
Accession
0000899243-18-001348
Insider Transaction Report
Form 4
Dylan-Hyde Tyler
Chief Legal Officer
Transactions
- Sale
Common Shares
2018-01-16$28.00/sh−45,000$1,260,000→ 25,204 total - Sale
Common Shares
2018-01-16$28.24/sh−1,110$31,346→ 25,204 total - Exercise/Conversion
Common Shares
2018-01-16$12.57/sh+19,890$250,017→ 45,094 total - Sale
Common Shares
2018-01-16$28.10/sh−19,890$558,909→ 25,204 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-01-16−1,110→ 36,663 totalExercise: $12.57Exp: 2026-07-15→ Common Shares (1,110 underlying) - Exercise/Conversion
Common Shares
2018-01-16$12.57/sh+1,110$13,953→ 26,314 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-01-16−19,890→ 5,237 totalExercise: $12.57Exp: 2026-07-15→ Common Shares (19,890 underlying)
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.50 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.75, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F4]This option was granted on July 15, 2016 with respect to 53,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.
- [F5]This performance-based option was granted on July 15, 2016 with respect to 26,667 Common Shares with 100% of the shares vesting within 12 months of the date of grant, subject to the satisfaction of mutually agreed upon performance metrics.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001682027
Filing Metadata
- Form type
- 4
- Filed
- Jan 17, 7:00 PM ET
- Accepted
- Jan 18, 5:38 PM ET
- Size
- 16.8 KB